THE DEAL, AT A GLANCE
4/4 explanations supportedSimnova
01What it doesSimnova develops immune cell therapies, including CAR-NK and in vivo CAR-T programs.Source-grounded · automated review · Explore ↗
Checked 2026-09-06 · Review due 2026-09-13
Read supporting source ↗Simnova develops immune cell therapies.…
02Who is involvedFoundation Capital, Qianji Capital and Pudong Venture Capital co-led; Zhangke Herun, Oriza and Youshan also joined.Source-grounded · automated review · Explore ↗
Checked 2026-09-06 · Review due 2026-09-13
Read supporting source ↗Foundation Capital, Qianji Capital, and…
03What happenedSimnova announced a Series B of close to 400 million CNY, roughly $60 million.Source-grounded · automated review · Explore ↗
04Why it mattersThe financing supports clinical advancement of Simnova’s CAR-NK and in vivo CAR-T pipeline.Interpretation · Explore ↗
Click a part to explore its evidence. Symbols are conceptual, not financial charts.Original record source ↗
Simnova · Financing Record
Explore source-linked visual explanations for Simnova. Unsupported claims are withheld while source review continues.
Record 11701 · Recorded date: 2026-09-04
Explore company records →